These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 2160147)
1. Transmission of human parvovirus B19 by coagulation factor concentrates. Williams MD; Cohen BJ; Beddall AC; Pasi KJ; Mortimer PP; Hill FG Vox Sang; 1990; 58(3):177-81. PubMed ID: 2160147 [TBL] [Abstract][Full Text] [Related]
2. Prevalence of human parvovirus B19 and TT virus in a group of young haemophiliacs in South Africa. Rubinstein R; Karabus CD; Smuts H; Kolia F; Van Rensburg EJ Haemophilia; 2000 Mar; 6(2):93-7. PubMed ID: 10781195 [TBL] [Abstract][Full Text] [Related]
3. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization. Santagostino E; Mannucci PM; Gringeri A; Azzi A; Morfini M; Musso R; Santoro R; Schiavoni M Transfusion; 1997 May; 37(5):517-22. PubMed ID: 9149778 [TBL] [Abstract][Full Text] [Related]
5. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort. Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D; Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442 [TBL] [Abstract][Full Text] [Related]
6. High prevalence of parvovirus B19 IgG antibodies among Dutch hemophilia patients. Mauser-Bunschoten EP; Zaaijer HL; van Drimmelen AA; de Vries S; Roosendaal G; van den Berg HM; Lelie PN Vox Sang; 1998; 74(4):225-7. PubMed ID: 9691402 [TBL] [Abstract][Full Text] [Related]
7. Human parvovirus infection in haemophiliacs first infused with treated clotting factor concentrates. Bartolomei Corsi O; Azzi A; Morfini M; Fanci R; Rossi Ferrini P J Med Virol; 1988 Jun; 25(2):165-70. PubMed ID: 2839609 [TBL] [Abstract][Full Text] [Related]
8. [Parvovirus B19 infection in patients with congenital blood coagulation disorders]. Aguilar Franco C; Lucía Cuesta JF; Ferrer Torres J; Omeñaca Teres M Med Clin (Barc); 1997 May; 108(17):641-6. PubMed ID: 9312580 [TBL] [Abstract][Full Text] [Related]
9. Contamination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2. Schneider B; Becker M; Brackmann HH; Eis-Hübinger AM Thromb Haemost; 2004 Oct; 92(4):838-45. PubMed ID: 15467916 [TBL] [Abstract][Full Text] [Related]
10. Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation. Soucie JM; Siwak EB; Hooper WC; Evatt BL; Hollinger FB; Transfusion; 2004 Aug; 44(8):1179-85. PubMed ID: 15265122 [TBL] [Abstract][Full Text] [Related]
11. Prevalence of nucleic acid sequences specific for human parvoviruses, hepatitis A and hepatitis E viruses in coagulation factor concentrates. Modrow S; Wenzel JJ; Schimanski S; Schwarzbeck J; Rothe U; Oldenburg J; Jilg W; Eis-Hübinger AM Vox Sang; 2011 May; 100(4):351-8. PubMed ID: 21133933 [TBL] [Abstract][Full Text] [Related]
12. Parvovirus B19 transmission by a high-purity factor VIII concentrate. Wu CG; Mason B; Jong J; Erdman D; McKernan L; Oakley M; Soucie M; Evatt B; Yu MY Transfusion; 2005 Jun; 45(6):1003-10. PubMed ID: 15935000 [TBL] [Abstract][Full Text] [Related]
13. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor VIII concentrates. Azzi A; Ciappi S; Zakvrzewska K; Morfini M; Mariani G; Mannucci PM Am J Hematol; 1992 Mar; 39(3):228-30. PubMed ID: 1312304 [TBL] [Abstract][Full Text] [Related]
14. Antiphospholipid antibodies in pediatric and adult patients with rheumatic disease are associated with parvovirus B19 infection. Von Landenberg P; Lehmann HW; Knöll A; Dorsch S; Modrow S Arthritis Rheum; 2003 Jul; 48(7):1939-47. PubMed ID: 12847688 [TBL] [Abstract][Full Text] [Related]
15. Transmission of human parvovirus B19 by plasma derived factor VIII concentrates. Laurian Y; Dussaix E; Parquet A; Chalvon-Demersay A; d'Oiron R; Tchernia G Nouv Rev Fr Hematol (1978); 1994 Dec; 36(6):449-53. PubMed ID: 7753615 [TBL] [Abstract][Full Text] [Related]
16. Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screening. Soucie JM; De Staercke C; Monahan PE; Recht M; Chitlur MB; Gruppo R; Hooper WC; Kessler C; Kulkarni R; Manco-Johnson MJ; Powell J; Pyle M; Riske B; Sabio H; Trimble S; Transfusion; 2013 Jun; 53(6):1217-25. PubMed ID: 22998193 [TBL] [Abstract][Full Text] [Related]
17. Transient hypoplastic anemia caused by primary human parvovirus B19 infection in a previously untreated patient with hemophilia transfused with a plasma-derived, monoclonal antibody-purified factor VIII concentrate. Matsui H; Sugimoto M; Tsuji S; Shima M; Giddings J; Yoshioka A J Pediatr Hematol Oncol; 1999; 21(1):74-6. PubMed ID: 10029819 [TBL] [Abstract][Full Text] [Related]
18. Effects of transfusion on human erythrovirus B19-susceptible or -infected pediatric recipients in a genotype 3-endemic area. Parsyan A; Addo-Yobo E; Owusu-Ofori S; Akpene H; Sarkodie F; Allain JP Transfusion; 2006 Sep; 46(9):1593-600. PubMed ID: 16965589 [TBL] [Abstract][Full Text] [Related]
19. Seroprevalence of human parvovirus B19 infection in Sao Tomé and Principe, Malawi and Mascarene Islands. Schwarz TF; Gürtler LG; Zoulek G; Deinhardt F; Roggendorf M Zentralbl Bakteriol; 1989 Jul; 271(2):231-6. PubMed ID: 2550018 [TBL] [Abstract][Full Text] [Related]
20. Parvovirus B19 antibodies in immunocompromized children in Thailand. Suandork P; Theamboonlers A; Likitnukul S; Hirsch P; Poovorawan Y Asian Pac J Allergy Immunol; 2000 Sep; 18(3):161-4. PubMed ID: 11270472 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]